Clinical Trial Update: Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of IFX-1 add-on to standard of care in GPA and MPA was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis

Drugs mentioned

• IFX-1 (vilobelimab)

Snippet

Sponsor: InflaRx GmbH | Conditions: Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Status: TERMINATED | Results posted: 2022-05-26